Compare Medpace Holdings Inc (MEDP) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Vanguard Total World Stock Index Fund ETF — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Vanguard Total World Stock Index Fund ETF trades at $159.83 (market cap $101.70B). The key difference: Vanguard Total World Stock Index Fund ETF is far larger — about 6× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 1,783,794). Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Vanguard Total World Stock Index Fund ETF for 53 Days on average.
| MEDP | VT | |
|---|---|---|
Market Cap | $16.82B | $101.70B |
Volume | 223,093 | 1,783,794 |
Sector | Health | Broad Market / Factor |
52-Week High | $630.19 | $162.39 |
52-Week Low | $393.42 | $134.19 |
Typical Hold Time | 14 Days | 53 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
VT trades at $158.73, down 0.57% on the day, with technical indicators showing a bearish bias as moving averages signal selling pressure. The ETF maintains its position as a comprehensive global equity vehicle with over 9,700 holdings and a 0.06% expense ratio. Recent news highlights VT's diversification benefits and cost competitiveness against peers like Schwab International Equity ETF and iShares MSCI World ETF.
The outlook remains favorable for long-term investors seeking broad global exposure, though near-term technical weakness suggests potential testing of support levels. Key risks include global market volatility and currency fluctuations, while institutional activity shows mixed positioning with recent sales by Barry Investment Advisors offset by new stakes from FAS Wealth Partners.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
